# Meropenem Versus Meropenem Plus Glycopeptide in Patients With Febrile Neutropenia After Allogenic Blood Stem Cell Transplantation

> **NCT00462878** · — · COMPLETED · sponsor: **PETHEMA Foundation** · enrollment: 392 (estimated)

## Conditions studied

- Allogenic Blood Stem Cell Transplantation
- Febrile Neutropenia

## Interventions

- **DRUG:** Meropenem
- **DRUG:** Vancomycin
- **DRUG:** Teicoplanin

## Key facts

- **NCT ID:** NCT00462878
- **Lead sponsor:** PETHEMA Foundation
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2002-11
- **Primary completion:** —
- **Final completion:** 2009-04
- **Target enrollment:** 392 (ESTIMATED)
- **Last updated:** 2009-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00462878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00462878, "Meropenem Versus Meropenem Plus Glycopeptide in Patients With Febrile Neutropenia After Allogenic Blood Stem Cell Transplantation". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00462878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*